U.S. Retail REITs Stock News

The planned rebuild of the Kirkuk to Mediterranean oil pipeline could reshuffle how crude moves out of the Middle East, and that matters for your portfolio. A more secure export route that reduces dependence on the Strait of Hormuz may ease oil price risk, and that can change the cost base for energy intensive sectors. This article looks at how that news links back to our Energy Intensive Industries screener and what it could mean for stock selection. You will see 3 stocks exposed to this...

Powell Industries has delivered an exceptionally strong long term share price return over the past five years, yet its current valuation checks lean expensive rather than cheap. Powell Industries has returned about 25x over the last five years, which puts extra focus on whether the current share price already reflects investors' expectations. Growing interest in power infrastructure for data centers can support elevated expectations for future earnings, but recent pressure on the share price...

Hewlett Packard Enterprise (HPE) is back in focus after expanding its partnership with ScanSource to distribute the HPE Juniper Networking portfolio, coinciding with fresh AI systems orders and higher earnings guidance. See our latest analysis for Hewlett Packard Enterprise. At a share price of $45.82, Hewlett Packard Enterprise has seen short term share price pressure, with a 7 day share price return down 5.60% and a 30 day share price return down 4.94%. This is set against strong momentum...

With softer U.S. inflation, shifting expectations for Federal Reserve rate moves, a weaker dollar and firmer oil prices, many investors are taking a fresh look at U.S. dividend stocks as potential sources of steady income and relative stability. This article focuses on large companies in traditionally resilient areas such as utilities, consumer staples, healthcare and industrials. All are drawn from a U.S. Dividend Stocks screener built around these macro shifts. You will see 3 stocks that...

Karooooo (KARO) reaffirmed its fiscal 2027 guidance after reporting Q1 2027 results, keeping the focus on subscription revenue, operating margins and earnings per share targets that management highlighted alongside record operating profit. See our latest analysis for Karooooo. Karooooo’s share price has risen 35.28% over the past month and 40.34% year to date, while the 3 year total shareholder return of 182.36% points to strong longer term momentum around the reaffirmed guidance and recent...

Construction Partners, Inc. previously announced it would release its fiscal 2026 third-quarter results on August 7, 2026, accompanied by an investor conference call that morning to discuss its performance. This update has drawn attention to the company’s improving free cash flow margins and acquisition-driven expansion, which are shaping how investors view its long-term fundamentals. Now we’ll examine how growing anticipation around the upcoming earnings release and improving free cash...

Barclays downgrade and 52 week low put LegalZoom.com (LZ) under the microscope LegalZoom.com (LZ) is back in focus after a Barclays downgrade and a slide to a fresh 52 week low, as investors reassess its growth outlook and its reaction to emerging AI tools. See our latest analysis for LegalZoom.com. The Barclays downgrade comes after a sharp rebound in LegalZoom.com’s recent share price performance, with a 30 day share price return of 38.6% and a 90 day gain of 18.95%. However, longer term...

Hinge Health stock has surged year to date, yet its valuation checks and pricing on traditional multiples suggest investors are now paying a premium rather than buying into a clear bargain. Year to date, Hinge Health has returned 91.2%, which puts recent enthusiasm for the stock front and center in any valuation discussion. The company’s ability to convert growth into durable cash flows can support current expectations, while any setback in scaling profitably may weigh heavily on what...

Earlier this week, UiPath reported its first-ever quarterly GAAP operating profit, highlighted progress in moving its AI agentic products from pilot to production, and noted it still has about US$414 million available under its share repurchase program. A three-year agreement to build an AI-driven pricing platform for UK online retailer The Very Group shows how UiPath’s automation and AI capabilities are being applied to complex, margin-sensitive retail decisions. Next, we’ll examine how...

Monster Beverage (MNST) is back in the spotlight after announcing a 2-for-1 stock split, paired with strong international sales, sharpening attention on whether the current valuation matches underlying fundamentals. See our latest analysis for Monster Beverage. Despite a small 1 day share price decline of 2.44% to about $97.50, Monster Beverage has enjoyed strong momentum recently, with a 90 day share price return of 27.09% and a 1 year total shareholder return of 65.25%. This keeps attention...

Why Dan Buffery’s Appointment Matters for Houlihan Lokey Stock Houlihan Lokey (HLI) recently announced that Dan Buffery has joined its Capital Solutions Group as a Managing Director, taking a lead role in North American GP-led secondaries advisory within Equity Capital Solutions. For you as an investor, this kind of senior hire is less about headlines and more about what it might indicate for the firm’s advisory depth in private equity secondaries, infrastructure, and real assets. See our...

In recent days, Bernstein Liebhard LLP began investigating potential fiduciary duty breaches by certain Gartner directors and officers, while investors also looked back on Gartner’s identification of leading AI semiconductor vendors and its publication of the 2026 Magic Quadrant for Conversational AI Platforms. At the same time, the market’s focus has shifted to Gartner’s upcoming Q2 fiscal 2026 earnings report, with analysts’ expectations and its track record of outperforming EPS estimates...

Recent Performance Context for V.F Stock Without a specific news catalyst, V.F (VFC) is attracting attention as investors weigh its recent share performance against reported annual revenue of US$9.6b and net income of US$254.9m. The stock is up in the past month but down over the past 3 months, with a contrasting 1 year total return gain and a weaker multi year track record. This mixed picture is shaping how investors assess V.F today. See our latest analysis for V.F. V.F’s recent 1 day share...

Ionis Pharmaceuticals (NasdaqGS:IONS) has dosed the first participant in the Phase 1-2 ASCEND trial of ION337 for Dravet syndrome. The study marks the first clinical evaluation of ION337, a next generation RNA targeted therapy candidate. ION337 has FDA Fast Track designation for Dravet syndrome, a rare seizure disorder with no approved disease modifying treatments. For investors following Ionis Pharmaceuticals, this new trial adds a fresh data point to the company’s rare disease portfolio...

Texas Capital Bancshares has delivered a 68.2% return over the past five years, yet the current valuation picture is mixed, with the Excess Returns intrinsic value estimate indicating the stock may trade below its estimated worth while market multiples sit closer to about right. A 68.2% return over five years points to a stock that has already rewarded patient shareholders, so the question is how much valuation upside may still be on the table. The appointment of Mo Jamous as Chief Digital...

The Cyclospora parasite outbreak linked to shredded iceberg lettuce at Taco Bell has pushed Yum! Brands (YUM) into the spotlight, with investors weighing food safety concerns alongside the company’s upcoming second quarter results on July 30. See our latest analysis for Yum! Brands. Recent trading reflects those concerns, with Yum! Brands’ share price down 2.75% over the past day and 9.55% over the past week. Its 1 year total shareholder return of 1.21% and 5 year total shareholder return of...

Mattel stock has had a tough run over the past three years, yet its current valuation checks lean cheap, which sets up a clear tension between weak long term returns and a market price that screens as potentially modestly undervalued. Mattel has declined 32.5% over the past three years, which means today’s valuation is being judged against a share price that has already come down meaningfully. On the upside, UBS has highlighted Mattel’s broad brand portfolio as a source of brand equity that...

Moody's (MCO) is back in focus after Intapp, Inc. expanded its collaboration to plug Moody's financial risk data directly into Intapp Celeste, an agentic AI platform used across legal, private capital, and accounting firms. See our latest analysis for Moody's. Against the backdrop of this Intapp collaboration, Moody's share price is trading at US$510.86, with a 30 day share price return of 11.98% and a 90 day share price return of 12.19%, while the 3 year total shareholder return of 46.33%...

LyondellBasell Industries (LYB) is in focus after unveiling a flexible packaging solution for Mondelez's Marabou chocolate bars, using ISCC PLUS-certified CirculenRevive polymers with 100% attributed recycled content. See our latest analysis for LyondellBasell Industries. LyondellBasell Industries shares recently closed at US$59.17, with a 1 day share price return of 2.37% and a 7 day return of 5.00%. Over the past 30 and 90 days, the share price returns declined 4.27% and 10.71%...

Cooling U.S. inflation, softer energy costs and a less aggressive Federal Reserve have shifted the focus back to dependable income stocks that can still grow their payouts. With annual inflation at 3.5% and core inflation at 2.6%, dividend growth stocks look interesting as potential anchors in portfolios that seek stability alongside income potential. This article walks through 3 dividend growers from our Dividend Growth Stocks screener that appear well positioned, based on their exposure to...

The recent move in Arcutis Biotherapeutics (ARQT) comes after the FDA accepted a supplemental application for ZORYVE cream 0.05%, which could extend its use to infants with mild to moderate atopic dermatitis. See our latest analysis for Arcutis Biotherapeutics. Against this backdrop, Arcutis Biotherapeutics’ recent 1-month share price return of 8.66% and 90-day share price return of 16.14% suggest improving momentum, while the year-to-date share price return has slightly declined 1.76%. Over...

Why Amgen’s Earnings Setup Is Drawing Attention Now Amgen (AMGN) is back in focus after a recent run of earnings surprises, with the stock drawing attention as investors weigh the implications of its track record and current earnings signals. See our latest analysis for Amgen. Beyond the earnings setup, Amgen’s share price has gained 7.21% over the past month and 11.80% year to date, while its 1 year total shareholder return of 28.00% points to momentum building over a longer period. If...

Ameriprise Financial recently welcomed the Sher Jeshiva Group to its branch channel from Wells Fargo Clearing Services, adding about US$470 million in client assets and reporting that more than 90% of the group’s clients agreed to move with them. This influx of advisory talent and portable assets comes as investors await Ameriprise’s late-July earnings release, where Wall Street expects higher revenue and earnings. We’ll now examine how the Sher Jeshiva Group’s US$470 million asset...

Apollo Global Management (APO) has moved into the spotlight after easyJet backed its surprise takeover offer, valuing the airline at about £5.7b and setting up a bidding contest with rival suitor Castlelake. See our latest analysis for Apollo Global Management. Beyond the EasyJet bid, Apollo Global Management has been busy on the deal front. It recently closed the acquisitions of Emerald Holding and Questex and combined them into a single B2B events and media platform. This comes at a time...